Product nameAnti-BLNK (phospho Y84) antibody [EP2202(2)]
See all BLNK primary antibodies
DescriptionRabbit monoclonal [EP2202(2)] to BLNK (phospho Y84)
Tested applicationsSuitable for: WBmore details
Unsuitable for: Flow Cyt,ICC/IF,IHC-P or IP
Species reactivityReacts with: Mouse, Rat, Human
Synthetic peptide (the amino acid sequence is considered to be commercially sensitive) within Human BLNK aa 50-150 (phospho Y84) (Cysteine residue). The exact sequence is proprietary.
Database link: Q8WV28
- Raji cell lysate, treated with pervanadate.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferpH: 7.20
Preservative: 0.01% Sodium azide
Constituents: 9% PBS, 40% Glycerol, 0.05% BSA, 50% Tissue culture supernatant
PurityTissue culture supernatant
Our Abpromise guarantee covers the use of ab174837 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/1000 - 1/5000. Detects a band of approximately 68-70 kDa (predicted molecular weight: 50 kDa).|
FunctionFunctions as a central linker protein that bridges kinases associated with the B-cell receptor (BCR) with a multitude of signaling pathways, regulating biological outcomes of B-cell function and development. Plays a role in the activation of ERK/EPHB2, MAP kinase p38 and JNK. Modulates AP1 activation. Important for the activation of NF-kappa-B and NFAT. Plays an important role in BCR-mediated PLCG1 and PLCG2 activation and Ca(2+) mobilization and is required for trafficking of the BCR to late endosomes. However, does not seem to be required for pre-BCR-mediated activation of MAP kinase and phosphatidyl-inositol 3 (PI3) kinase signaling. May be required for the RAC1-JNK pathway. Plays a critical role in orchestrating the pro-B cell to pre-B cell transition (By similarity). Plays an important role in BCR-induced B-cell apoptosis.
Tissue specificityExpressed in B-cell lineage and fibroblast cell lines (at protein level). Highest levels of expression in the spleen, with lower levels in the liver, kidney, pancreas, small intestines and colon.
Involvement in diseaseDefects in BLNK are the cause of agammaglobulinemia type 4 (AGM4) [MIM:613502]. It is a primary immunodeficiency characterized by profoundly low or absent serum antibodies and low or absent circulating B cells due to an early block of B-cell development. Affected individuals develop severe infections in the first years of life.
Sequence similaritiesContains 1 SH2 domain.
modificationsFollowing BCR activation, phosphorylated on tyrosine residues by SYK and LYN. When phosphorylated, serves as a scaffold to assemble downstream targets of antigen activation, including PLCG1, VAV1, GRB2 and NCK1. Phosphorylation of Tyr-84, Tyr-178 and Tyr-189 facilitates PLCG1 binding. Phosphorylation of Tyr-96 facilitates BTK binding. Phosphorylation of Tyr-72 facilitates VAV1 and NCK1 binding. Phosphorylation is required for both Ca(2+) and MAPK signaling pathways.
Cellular localizationCytoplasm. Cell membrane. BCR activation results in the translocation to membrane fraction.
- Information by UniProt
- AGM4 antibody
- B cell adapter containing SH2 domain protein antibody
- B cell adapter containing Src homology 2 domain protein antibody
All lanes : Anti-BLNK (phospho Y84) antibody [EP2202(2)] (ab174837) at 1/1000 dilution
Lane 1 : Raji cell lysate, untreated
Lane 2 : Raji cell lysate, treated with pervanadate
Lysates/proteins at 10 µg per lane.
All lanes : Goat anti-rabbit HRP at 1/2000 dilution
Developed using the ECL technique.
Predicted band size: 50 kDa
ab174837 has not yet been referenced specifically in any publications.